Patent details

Basic Information

Publication number:

92596

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP979371481

Legal Status:

Expired

Application number:

92596

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/14/923 Entyvio (Vedolizumab)

Marketing Authorization Type:

Marketing Authorization Date:

22/05/2014

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

12/11/2014

First Marketing Authorization date:

22/05/2014

Grant date:

12/01/2015

Activation date:

06/08/2017

Publication date:

12/01/2015

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

06/08/2022

SPC Extension Expiration:

06/08/2022

Rejection date:

Withdrawal date:

Owner

From:

12/11/2014

 

 

Name:

MILLENNIUM PHARMACEUTICALS INC.

Address:

75 Sidney Street, Cambridge, Massachusetts 02139, United States (US)

Agent

Name:

KIRKPATRICK SA / NV

From:

12/11/2014

Address:

AVENUE WOLFERS 32, 1310, LA HULPE, Belgium (BE)

To:

Inventor

1

Name:

PONATH Paul, D.

Address:

United States (US)

2

Name:

RINGLER Douglas, J.

Address:

United States (US)

3

Name:

NEWMAN Walter

Address:

United States (US)

4

Name:

SALDANHA José

Address:

United Kingdom (GB)

5

Name:

JONES S., Tarran

Address:

United Kingdom (GB)

6

Name:

BENDIG Mary, M.

Address:

United Kingdom (GB)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2017/05

Publication date:

13/09/2017

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

25/08/2021

Last Annual Fee Paid Number:

25

Last Annual Fee Paid Amount:

450 Euro

Payer:

KIRKPATRICK SA / NV

Filing date	Document type	Number of pages